Insight Molecular Diagnostics Inc. IMDX 深 沪
等待开盘 07-03 09:30:00 美东时间
5.74
+0.050
+0.88%
华盛通- 最 高6.02
- 今 开5.75
- 成交量 14.20万股
- 最 低 5.51
- 昨 收 5.69
- 总市值 1.85亿
- 52周最高 8.51
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.33
- 委 比 -98.93%
- 总股本 3229.02万
- 历史最高 204.80
- 量 比 1.09
- 振 幅 8.96%
- 历史最低 1.922
- 每 手 1
- 风险率 1.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
Insight Molecular Diagnostics Inc. (iMDx) announced that its Chief Science Officer, Prof. Dr. Ekkehard Schuetz, has published his 200th scientific article. With an H-index of 58, Schuetz ranks in the top 2.5% of researchers globally and top 2% in laboratory diagnostics. He co-invented the dd-cfDNA technology behind iMDx’s GraftAssure family of assays, which aims to revolutionize transplanted organ rejection monitoring. Schuetz’s work has advanced...
06-29 12:00
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
Insight Molecular Diagnostics Inc. (iMDx) and the American Society of Transplant Surgeons (ASTS) have awarded a $100,000 grant to Drs. Kenneth Andreoni and Kenneth Chavin to study the health economics of in-house versus send-out dd-cfDNA testing in kidney transplantation. The research aims to compare costs, clinical impact, and operational efficiency to guide transplant programs in choosing diagnostic testing strategies. The findings will support...
06-22 18:07
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
Insight Molecular Diagnostics Inc. (iMDx) will showcase its GraftAssure technology at the American Transplant Congress in Boston, highlighting its potential benefits and utility in transplanted organ rejection monitoring. The company will present favorable third-party head-to-head data, host events to discuss the future of transplant monitoring, and announce a grant to evaluate the economics of in-house testing. GraftAssure aims to provide faster...
06-09 20:05
Insight Molecular Diagnostics shares are trading higher. The company reported its Q1 financial results.
Insight Molecular Diagnostics shares are trading higher. The company reported i...
05-15 00:24
Insight Molecular Q1 2026 Earnings Call Transcript
Insight Molecular (NASDAQ:IMDX) held its first-quarter earnings conference call...
05-14 17:03
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Alpha Buying: Insider Conviction in High-Risk Biotech
Insider buying matters in every industry, but it carries a special weight in bi...
05-08 00:04
iMDx to Release First Quarter 2026 Results on May 13, 2026
Insight Molecular Diagnostics Inc. (IMDX) announced it will release its first quarter 2026 financial results after market close on May 13, 2026, followed by a live Zoom webinar at 2:00 pm PT / 5:00 pm ET to discuss the results. Registration for the webinar is available at the provided link, and an archived replay will be accessible on the company’s website post-event. The company aims to improve patient outcomes through innovative molecular diagn...
05-06 20:05
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Apellis Pharmaceuticals (NASDAQ:APLS) shares moved upwards by 138.8% t...
03-31 20:05
Insight Molecular Diagnostics Files GraftAssureDx For Kidney Transplant Rejection Testing For FDA Review
Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results.Submitted GraftAssureDx™ for kidney transplant
03-27 04:16
